Multiple Myeloma: KOL Insight 2020

Multiple Myeloma: KOL Insight

Darzalex has been one of the leading success stories in recent years, but will it become a standard-of-care first line therapy for all newly diagnosed patients? KOLs expect new approaches targeting BCMA with ADCs, CAR-T and bispecific antibodies will significantly impact the treatment paradigm but which products are generating most excitement? US and European KOLs critically assess the prospects of launched and pipeline therapies.

Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.

I want an edge. Let's talk

Key questions answered

In what setting do KOLs see value in Takeda's orally administered Ninlaro (ixazomib)?
What advantages do KOLs see for GSK's 'off-the-shelf' ADC belantamab mafodotin in targeting BCMA?
What safety issues do KOLs identify as hampering Karyopharm's selective inhibitor of nuclear export Xpovio (selinexor)?
What impact has Covid-19 had on the treatment of Multiple Myeloma patients and how might this affect future treatment practice?

Examples of Therapies Covered

•

Iberdomide

•

Kyprolis

•

Ninlaro

•

Darzalex

•

Translarna

•

Viltepso

•

Empliciti

•

Sarclisa

•

Xpovio

•

Venetoclax

•

Bispecific antibodies

•

CAR-T therapies

Partial List of Participating KOLs

Professor at the Translational Genomics Research Institute (TGen) and Chief Medical Officer of the International Myeloma Foundation, US
Professor of Medicine, Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, US
Professor of Medicine, Oncology Division, Washington University School of Medicine, US
Professor of Clinical Haematology/Head of Haematology Department, University Hospital Hôtel-Dieu, France
Consultant haematologist and Honorary Senior Lecturer, Central Manchester University Hospitals NHS Foundation Trust, UK
Associate Professor of Oncology, Centre Hospitalier de Périgueux, France

Contact us for a full list of KOLs

We engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.

Our-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.

Our reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.

Continuous Monitoring Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.	Boardroom Ready Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Future Driven Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.	Deep Dive Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.

Contact Us
First Name*
Last Name*
Email*
Job Title*
Phone*
Company Name *
Country Name *
Company
Job Function
Clean_Company
World_Region
FW_Sub_Type
ProductName
Brand_Name
Account Owner
Account_Type
Lead_Type
Product_Code
UID

Contact Us

Multiple Myeloma: KOL Insight 2020

Browse by